105 results about "Follicular stimulating hormone" patented technology

This invention provides pyrrolobenzodiazepine pyridine carboxamides selected from those of Formula (1), which act as follicle stimulating hormone receptor antagonists. The invention also provides pharmaceutical compositions and methods of treatment utilizing the compounds of Formulae (1) and (2).

The present invention relates to a system for assessing ovarian reserve functions in subjects. The system for assessing the ovarian reserve functions of the subjects comprises a data acquisition module used for obtaining data of a subject's age, an anti-Mullerian hormone (AMH) level, a follicle stimulating hormone (FSH) level and antral follicle counting (AFC); and a module for calculating the ovarian reserve functions used for calculating information obtained in the data acquisition module to calculate a probability (p) of subject's ovarian hyporesponsiveness. Further, a relationship betweenthe predicted ovarian hyporesponsiveness probability and a medicine dose of an ovulation-promoting medicine is predicted to divide populations into four groups in order to group closes ovarian responsiveness into one group.

A method for synchronizing ovulation in sows and gilts by a single injection of hormones is disclosed. A hormone, gonadotropin releasing hormone (GnRH), luteinizing hormone (LH), follicle stimulating hormone (FSH), human chorionic gonadotropin (hCG), analogues, derivatives, agonists or combinations thereof is administered to an open sow post weaning at a specific time to stimulate ovulation of mature responsive follicles. The sow is then bred, without heat detection, at a specific subsequent timed interval after injection with hormone, with one or two artificial or natural breedings. In gilts, the hormone is injected at a timed interval from onset of estrus or at a specific timed interval following Prostaglandin F2a for those gilts which have been held in a state of pseudopregnancy.

A method for synchronizing ovulation in sows and gilts by a single injection of hormones is disclosed. A hormone, gonadotropin releasing hormone (GnRH), luteinizing hormone (LH), follicle stimulating hormone (FSH), human chorionic gonadotropin (hCG), analogues, derivatives, agonists or combinations thereof is administered to an open sow post weaning at a specific time to stimulate ovulation of mature responsive follicles. The sow is then bred, without heat detection, at a specific subsequent timed interval after injection with hormone, with one or two artificial or natural breedings. In gilts, the hormone is injected at a timed interval from onset of estrus or at a specific timed interval following Prostaglandin F2a for those gilts which have been held in a state of pseudopregnancy.

The invention relates to a system for predicting the number of oocytes obtained during ovarian stimulation of an object receiving a standard GnRH antagonist solution for ovulation induction. The system comprises a data acquisition module used for obtaining data of the anti-mullerian hormone (AMH) level, basal follicle stimulating hormone (FSH) level and antrum follicle count (AFC) of the object and a module used for predicting the number of the oocytes obtained during the ovarian stimulation and calculating the information obtained in the data acquisition module to calculate the number of theoocytes (NROs) obtained by the object.

The invention discloses a urinary follicle stimulating hormone with a purity of no more than 95w / w%; and the impurity content is not more than 5w / w%. Simultaneously, the invention discloses a preparation method for the urinary follicle stimulating hormone with high purity.

The invention relates to a urethrotropin freeze-dried powder injection and a preparation method thereof. In every 1 mg freeze-dried powder injection: the active ingredient is 60-200 units based on the titer of follicle-stimulating hormone, and the auxiliary materials are L-arginine, The composition of mannitol and phosphate buffer salt is 4-8:20-40:2.0-6.0 according to the weight ratio. The formula of the present invention prevents the urea gonadotropin from existing in the aqueous solution state for a long time in the preparation process, reduces the freeze-drying time, and increases the stability of the urea gonadotropin freeze-dried powder injection.

The invention provides recombinant native and mutein forms of human follicle stimulating hormone beta subunit (FSH beta) with characteristic glycosylation patterns which are influential in the metabolic activity of the protein. The invention also provides recombinant mutant forms of the human alpha subunit common to FSH, LH, CG, and TSH, to obtain hormones which also have unique glycosylation patterns. Also provided are recombinant materials to produce these subunits separately or together to obtain complete heterodimeric hormones of regulated glycosylation pattern.

The present invention is directed to a method of using dehydroepiandrosterone (DHEA) to treat a human female with diminished ovarian reserve. The method includes measuring a baseline follicle stimulating hormone (FSH) level of the human female, and when the baseline FSH level is below about 40.0 mIU / ml, administering about 75 milligrams of DHEA per day to the female for at least four months to treat ovarian follicles in at least one ovary of the female to improve human folliculogenesis during the at least four months. The present invention further is directed to a method of restoring the ovarian environment of an older human female to that of a younger human female. The method includes administering about 75 milligrams of DHEA per day to the female for at least four months.

The present invention provides methods of producing biologically active recombinant eFSH analogs and methods of increasing reproduction in mammals, particularly equine, using recombinant eFSH analogs. Also provided are methods of producing biologically active single chain recombinant eFSH. The recombinant eFSH analogs of the present invention increase superovulation, follicular development, embryo development, and reproductive efficiency in horses, cattle and other ungulates.

The invention provides a follicle stimulating hormone (FSH) preparation with high sialylation and high efficacy.

The invention provides novel heterodimeric fusion proteins comprising a first polypeptide including an alpha subunit of FSH (αFSH) linked directly or indirectly to a binding partner of neonatal Fc receptor (FcRn) and a second polypeptide including a beta subunit of FSH (βFSH) linked directly or indirectly to an FcRn binding partner. In one embodiment the FcRn binding partner includes an Fc fragment of an immunoglobulin, e.g., an Fc fragment of IgG. Also provided are methods making and using the fusion proteins of the invention. The invention provides a method for increasing fertility in a subject and a method for treating a subject having a disease state responsive to treatment by FSH.

The present invention relates to a long-acting human follicle-stimulating hormone formulation having improved in vivo duration and stability, comprising a human follicle-stimulating hormone conjugate that is prepared by covalently linking human follicle-stimulating hormone with an immunoglobulin Fc region via a non-peptidyl polymer, and a preparation method thereof. The long-acting human follicle-stimulating hormone formulation of the present invention maintains in vivo activity of human follicle-stimulating hormone at a relatively high level and remarkably increases the serum half-life thereof.

The present invention relates to a method for mass-production of human follicle stimulating hormone, more precisely, to an expression vector containing human follicle stimulating hormone gene, a transformant transfected with the expression vector and a method for mass-production of human follicle stimulating hormone by using the same. Human follicle stimulating hormone can be produced largely by using an expression vector and a transformant of the present invention. Therefore the expression vector and the transformant of the present invention can be effectively used for the treatment of infertility.

The invention provides a veterinary follicle-stimulating hormone analogue and a preparation method thereof. A connecting sequence is designed according to length, foldability, hydrophobicity and charge effect of a connecting sequence between an alpha peptide chain and a beta peptide chain, the corresponding nucleotide sequence of the connecting sequence is any one of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19 and SEQ ID NO:20, and respective expression quantity and biological activity are compared by virtue of the study. A fused protein of the prepared veterinary follicle-stimulating hormone analogue is similar to the known fused protein in term of biological functions, the expression quantity of multiple fused proteins is obviously increased, the veterinary follicle-stimulating hormone analogue can be used for replacing natural ovarian-stimulating hormone, has great commercial value and is worthy of wide-range popularization.